News | June 25, 2024
Venus Remedies clinches WHO-backed PAHO tender
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Subscribe To Our Newsletter & Stay Updated
